105 related articles for article (PubMed ID: 7882180)
1. meta-iodobenzylguanidine uptake in the hypertensive-diabetic rat heart: a marker for myocardial dysfunction?
Herman LM; Dai S; Hartman NG; McNeill JH
Can J Physiol Pharmacol; 1994 Oct; 72(10):1162-7. PubMed ID: 7882180
[TBL] [Abstract][Full Text] [Related]
2. Cardiac iodine-123 metaiodobenzylguanidine uptake in animals with diabetes mellitus and/or hypertension.
Dubois EA; Kam KL; Somsen GA; Boer GJ; de Bruin K; Batink HD; Pfaffendorf M; van Royen EA; van Zwieten PA
Eur J Nucl Med; 1996 Aug; 23(8):901-8. PubMed ID: 8753678
[TBL] [Abstract][Full Text] [Related]
3. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
[TBL] [Abstract][Full Text] [Related]
4. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: implications for heterogeneous cardiac accumulation of MIBG in diabetes.
Kiyono Y; Iida Y; Kawashima H; Tamaki N; Nishimura H; Saji H
Eur J Nucl Med; 2001 Jul; 28(7):894-9. PubMed ID: 11504086
[TBL] [Abstract][Full Text] [Related]
5. Myocardial performance of STZ-diabetic DOCA-hypertensive rats.
Dai S; McNeill JH
Am J Physiol; 1992 Dec; 263(6 Pt 2):H1798-805. PubMed ID: 1481903
[TBL] [Abstract][Full Text] [Related]
6. Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: implications for heterogeneous accumulation of MIBG.
Kiyono Y; Kajiyama S; Fujiwara H; Kanegawa N; Saji H
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):993-7. PubMed ID: 16261676
[TBL] [Abstract][Full Text] [Related]
7. Use of [123I]MIBG to assess cardiac adrenergic innervation: experience in hypertensive cardiopathy and left ventricular aneurysms.
Giordano A; Calcagni ML; Rufini V; Colivicchi F; Melina D; Melina G; Pristipino C; Nori S; Trani C; Santarelli P
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):44-8. PubMed ID: 9002748
[TBL] [Abstract][Full Text] [Related]
8. Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: implications for heterogeneous accumulation of MIBG.
Kiyono Y; Kajiyama S; Fujiwara H; Kanegawa N; Saji H
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):438-42. PubMed ID: 15821963
[TBL] [Abstract][Full Text] [Related]
9. Integrated cardiovascular function in the conscious streptozotocin-diabetic deoxycorticosterone-acetate-hypertensive rats.
Schenk J; Hebden RA; Dai S; McNeill JH
Pharmacology; 1994 Apr; 48(4):211-5. PubMed ID: 8177907
[TBL] [Abstract][Full Text] [Related]
10. Myocardial uptake of meta-[123I]-iodobenzylguanidine [( 123I]-MIBG) in patients with myocardial infarct.
Fagret D; Wolf JE; Comet M
Eur J Nucl Med; 1989; 15(9):624-8. PubMed ID: 2574671
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of norepinephrine content in the myocardium in hypertensive patients with left ventricular hypertrophy].
Schwebel C; Fagret D; Tremel F; Siché JP; Boutelant S; de Gaudemaris R; Mallion JM
Arch Mal Coeur Vaiss; 1992 Aug; 85(8):1099-102. PubMed ID: 1482241
[TBL] [Abstract][Full Text] [Related]
12. Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy.
Simmons WW; Freeman MR; Grima EA; Hsia TW; Armstrong PW
Circulation; 1994 Jun; 89(6):2843-51. PubMed ID: 8205700
[TBL] [Abstract][Full Text] [Related]
13. [Action of labetalol on norepinephrine myocardial content in left ventricular hypertrophy in hypertensive patients].
Schwebel C; Fagret D; Tremel F; Siché JP; Boutelant S; de Gaudemaris R; Mallion JM
Arch Mal Coeur Vaiss; 1992 Aug; 85(8):1103-6. PubMed ID: 1482242
[TBL] [Abstract][Full Text] [Related]
14. Alterations of myocardial sympathetic innervation in response to hypoxia.
Scherrer-Crosbie M; Mardon K; Cayla J; Syrota A; Merlet P
J Nucl Med; 1997 Jun; 38(6):954-7. PubMed ID: 9189149
[TBL] [Abstract][Full Text] [Related]
15. Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure.
Somsen GA; van Vlies B; de Milliano PA; Borm JJ; van Royen EA; Endert E; Lie KI
Heart; 1996 Sep; 76(3):218-22. PubMed ID: 8868979
[TBL] [Abstract][Full Text] [Related]
16. Effects of hypothyroidism and thyrotoxicosis on metaiodobenzylguanidine kinetics in the rat heart.
Glowniak JV; Patrick ST; Urman SM; Turner FE
Nucl Med Commun; 1991 Oct; 12(10):879-84. PubMed ID: 1792023
[TBL] [Abstract][Full Text] [Related]
17. Myocardial m-[123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function.
Kreiner G; Wolzt M; Fasching P; Leitha T; Edlmayer A; Korn A; Waldhäusl W; Dudczak R
Diabetes; 1995 May; 44(5):543-9. PubMed ID: 7729613
[TBL] [Abstract][Full Text] [Related]
18. Reduced myocardial 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients.
Schnell O; Muhr D; Weiss M; Dresel S; Haslbeck M; Standl E
Diabetes; 1996 Jun; 45(6):801-5. PubMed ID: 8635656
[TBL] [Abstract][Full Text] [Related]
19. Scintigraphic imaging with 123I-metaiodobenzylguanidine as a marker of cardiac adrenergic neurotransmission in the rat.
Gayheart-Walsten P; Snyder D; Mack J; Boland C; Roberts J
Methods Find Exp Clin Pharmacol; 1995 May; 17(4):249-54. PubMed ID: 7475511
[TBL] [Abstract][Full Text] [Related]
20. Technetium-99m labeled 1-(4-fluorobenzyl)-4-(2-mercapto-2-methyl-4-azapentyl)-4-(2-mercapto-2-methylpropylamino)-piperidine and iodine-123 metaiodobenzylguanidine for studying cardiac adrenergic function: a comparison of the uptake characteristics in vascular smooth muscle cells and neonatal cardiac myocytes, and an investigation in rats.
Samnick S; Scheuer C; Münks S; El-Gibaly AM; Menger MD; Kirsch CM
Nucl Med Biol; 2004 May; 31(4):511-22. PubMed ID: 15093822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
